In a decisive meeting held on April 8-9, 2025, the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) approved several new veterinary vaccines and medications. The session, conducted in person at the EMA headquarters in Amsterdam, focused on enhancing the regulatory framework for veterinary medicines across the European Union.
Key Approvals and Recommendations
The CVMP granted approval for multiple vaccines, including Nobilis Multriva IBm+ND for chickens, targeting avian infectious bronchitis and Newcastle disease. Similarly, Nobilis Multriva Gm+REOm was approved to combat infectious bursal disease and avian reovirus in poultry. Additionally, the committee adopted the Emevet vaccine for dogs, designed to prevent chemotherapy-induced nausea and motion sickness. These approvals reflect the CVMP’s ongoing commitment to improving animal health through rigorous evaluation and endorsement of effective veterinary treatments.
Committees and Appointments
The meeting also addressed organizational matters, including the election of A. Pfalzgraff to the Novel Therapies & Technologies Working Party (NTWP) and the endorsement of new members for the Pharmacovigilance Working Party (PhVWP-V). The CVMP emphasized transparency by affirming that no conflicts of interest were declared by the participants, ensuring unbiased decision-making processes. Furthermore, the committee reviewed applications for marketing authorizations and discussed variations to existing authorizations to align product information with updated regulatory templates.
– Approval of vaccines targeting multiple strains and diseases in poultry and dogs.
– Strengthened pharmacovigilance through the appointment of new working party members.
– Enhanced regulatory alignment by updating product information templates.
EMA’s CVMP meeting underscored the agency’s proactive approach in addressing emerging veterinary health challenges. By approving essential vaccines and refining regulatory measures, the committee ensures that veterinary medicines remain safe, effective, and up-to-date with current scientific standards. Stakeholders can expect continued advancements in veterinary pharmacology, fostering better health outcomes for animals across the EU. The committee’s thorough evaluation process and transparent decision-making bolster confidence in the regulatory framework governing veterinary medicines, ultimately benefiting both animal health and public safety.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
